MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere™ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.
Under the agreement, the two organizations aim to advance drug development and discovery projects utilizing the MOS platform, which enables translational research on...
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
MD Anderson Research Highlights for July 27, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Eisbach Bio announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.
The agreement aligns the drug discovery and development expertise of MD Anderson’s Therapeutics Discovery division with the innovative discovery platform and allosteric assay technology...
Blood test helps predict who may benefit from lung cancer screening
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer...
MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration...
MD Anderson and the Rare Cancer Research Foundation launch collaboration to accelerate the development of treatments for rare cancers
The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation today announced the launch of a collaboration designed...
MD Anderson launches community-led Be Well™ Acres Homes initiative
With the launch of Be Well™ Acres Homes, The University of Texas MD Anderson Cancer Center unites more than 30 organizations, alongside community...
Link between inflammation and pancreatic cancer development uncovered
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection...
Classifying EGFR mutations by structure and function offers better way to match non-small cell lung cancer patients to treatments
Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations...